Which apps are useful for preparing for CSE

Biovaxys and the World Ovarian Cancer Coalition join forces in preparation for May 8th, World Ovarian Cancer Day

Vancouver, Bc and Toronto (OTS) - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) ("BioVaxys"), the world's leading provider of haptenized protein vaccines for antiviral and cancer applications, today announced its sponsorship of this year's World Ovarian Cancer Day, a major one Initiative of the World Ovarian Cancer Coalition ("the Coalition"), an international non-profit organization based in Canada.

World Ovarian Cancer Day was launched on May 8, 2013 by a group of leading stakeholders in the fight against ovarian cancer to provide a platform for everyone involved to show solidarity. The coalition works on many fronts, but World Ovarian Cancer Day is their main awareness-raising initiative and is supported by over 170 partner organizations from around the world. BioVaxys joins other partner companies including GSK, AstraZeneca, Novocure, Merck, Clovis Oncology, IMV, Teckro, Immunogen and AOA. Not only individuals but also organizations around the world, from small volunteer-run groups to established national organizations, support this leading initiative. The coalition believes that more can be achieved in the fight against ovarian cancer in community and welcomes all interested parties and stakeholders who work to raise awareness of the disease, both locally and internationally.

James Passin, Chief Executive Officer of BioVaxys, said, "We are honored to partner with the World Ovarian Cancer Coalition in supporting this important international advocacy group for ovarian cancer patients. We are approaching World Ovarian Cancer Day and BioVaxys is committed to BVX -0918A through clinical and commercial development. "

BioVaxys recently announced that its ovarian cancer vaccine, BVX-0918A, has partnered with Spanish biopharmaceutical company ProCare Health Iberia S.A.S. cooperates. ProCare Health Iberia S.A.S. intends to submit an application for clinical testing ("CTA") for BVX-0918A to the European Medicines Agency ("EMEA") for approval in stage III and IV ovarian cancer later this year. ProCare Health will receive marketing rights for BVX-0918A in the EU and the UK, while BioVaxys will commercialize its ovarian cancer vaccine in North America and the rest of the world.

Clara MacKay, Chief Executive Officer of the World Ovarian Cancer Coalition, said: "We are excited to partner with BioVaxys on World Ovarian Cancer Day 2021. We are especially excited to work with partner companies that are working hard to find new approaches to combating this devastating disease to develop."

There remains a significant unmet need for therapies to treat ovarian cancer. Over 300,000 women worldwide are diagnosed with ovarian cancer each year (World Cancer Research Fund, 2020), with ovarian cancer being the leading cause of death from gynecological malignancies in the United States (American Cancer Society Facts & Figures 2020). In the United States, an estimated 21,750 new cases of ovarian cancer and 13,940 deaths were expected in 2020 (National Cancer Institute, Surveillance and Epidemiology Program, 2020). Ovarian cancer is usually asymptomatic in its early stages (stages I and II), so around 80% of patients are diagnosed with advanced disease (stages III and IV). The 5-year survival rate for stage III and IV patients is approximately 29%. (1) The majority of women with stage III or IV cancer eventually have a relapse that does not respond to chemotherapy. Patients who have cancer recurring after platinum-based chemotherapy have a limited life expectancy even with multiple repeat treatments. This large group of patients who are unresponsive to primary therapy or who relapse is the original target market for BioVaxys. The global ovarian cancer drug market was estimated at $ 1.2 billion in 2017 and is projected to reach $ 4.6 billion by 2026, with a CAGR of 18.29% (www.medgadget.com/2020/11/ovarian-cancer -drugs-2020-global-market-to-reach-us-4-6-bn-and-growing-at-cagr-of-18-29-by-2026.html.)

Source: (1) American Cancer Society, Cancer facts and figures; (2) Cannistra SA. Cancer of the Ovary. (Ovarian cancer) N Engl J Med 2004 Dec 9; 351 (24): 2519-29; and (3) McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. (Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.) N Engl J Med 1996; 334 (1): 1-6.

About BioVaxys Technology Corp.

Vancouver-based BioVaxys Technology Corp. is an early stage biotechnology company registered in British Columbia developing viral and oncological vaccine platforms and immunodiagnostics. The company is advancing a SARS-CoV-2 vaccine based on its haptenized viral protein technology and plans to conduct a clinical trial of its haptenized autologous cell vaccine in combination with anti-PD1 and anti-PDL-1 checkpoint inhibitors, initially to be developed for ovarian cancer. Also under development is a diagnostic to assess the presence or absence of a T-cell immune response to SARS-CoV-2, the virus that causes COVID-19. BioVaxys has two issued U.S. patents and two patent applications relating to its cancer vaccine and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies. BioVaxys' common stock is listed on the CSE under the symbol "BIOV" and is listed on the Frankfurt Stock Exchange (FRA: 5LB) and US OTC: LMNGF.

ON BEHALF OF THE BOARD OF DIRECTORS

Signed "James Passin"

James Passin, CEO

+1 646 452 7054

Cautionary Notes Regarding Forward-Looking Information
This press release contains certain "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of applicable Canadian and US securities laws including the United States Private Securities Litigation Reform Act of 1995. Any statements contained herein that may not differ Relating to historical facts, in particular statements about the future operational or financial performance of the company, are forward-looking statements. Forward-looking statements are often, but not always, identified by words such as "expects," "anticipates," "believes," "intends," "estimates," "potentially", "possible" and similar expressions, or statements that will occur , Conditions or results "will", "may", "could" or "should". Forward-looking statements in this press release relate, among other things, to the completion of the mouse model study, regulatory approval for a Phase I human vaccine candidate BVX-0320, and the general development of BioVaxys' vaccines, including a haptenized SARS-Cov -2 protein vaccine. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those expressed or implied in such forward-looking statements. These forward-looking statements reflect the beliefs, opinions and projections at the time the statements were made and are based on a number of assumptions and estimates, most notably the belief that BioVaxys will be successful in developing and testing vaccines will be. These assumptions and estimates are accepted by the company as

Inquiries & contact:

e BioVaxys Technology Corp .:
Nikita Sachdev
Luna PR
[email protected]